Header Logo

Connection

TAREQ ABUASAB to Vidarabine

Back to Details
This is a "connection" page, showing publications TAREQ ABUASAB has written about Vidarabine.
TAREQ ABUASAB
Connection Strength
0.052
Vidarabine
  1. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.